Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for OSE2101 comprises 3 peer-reviewed publications across 3 journals, 1 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung, and Ovarian Neoplasms. Most recent publication: A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours., Eur J Cancer, 2026.
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.
| Trial | Indication | Primary endpoint | Arm | Value |
|---|---|---|---|---|
| NCT02654587 ATALANTE-1 | Carcinoma, Non-Small-Cell Lung | Overall Survival (OS) Approx. 24 months | Docetaxel or Pemetrexed | 7.5 Months |
| OSE2101 | 11.1 Months |
2023–2026: 3 publications.
In the ATALANTE-1 study (NCT02654587), which investigated OSE2101 in patients with Non-Small-Cell Lung Carcinoma, the median Overall Survival for the OSE2101 arm was 11.1 Months. For the Docetaxel or Pemetrexed arm in the same study, the median Overall Survival was 7.5 Months.
All values presented here are sourced from primary registry reporting; individual scientific papers should be consulted for comprehensive clinical context and decision-making.
ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.efetch.fcgi